← Barinthus Biotherapeutics plc.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
ASSETS
Current assets:
Cash and Cash Equivalents, at Carrying Value $43.3m $214.1m $194.4m $142.1m $110.7m $70.5m
Prepaid Expense and Other Assets, Current $1.4m $6.5m $8.3m $9.9m $6.2m $4.8m
Research and development incentives receivable $2.7m $6.2m $4.5m $4.9m $7.1m $1.1m
Prepaid expenses and other current assets $1.4m $6.5m $8.3m $9.9m $6.2m $4.8m
Accounts Receivable — $20k $5.8m $0 — —
Cash Cash Equivalents And Short Term Investments — — $194.4m $142.1m $110.7m $70.5m
Other Current Assets — — $611k $1.5m $344k $115k
Other Receivables — — $12.2m $10.3m $7.1m $1.1m
Prepaid Assets — $4.6m $5.9m — $5.9m $4.5m
Taxes Receivable — — $0 $3.0m $0 $197k
Assets, Current $47.9m $226.8m $213.0m $156.9m $125.7m $77.8m
Total current assets $47.9m $226.8m $213.0m $156.9m $125.7m $77.8m
Property, Plant and Equipment, Net $629k $1.8m $8.0m $11.8m $7.4m $3.5m
Goodwill — $12.6m $12.2m $12.2m $0 —
Intangible Assets, Net (Excluding Goodwill) — $31.4m $28.3m $25.1m $21.9m $14.3m
Goodwill And Other Intangible Assets — — $40.5m $37.3m $21.9m $14.3m
Other Intangible Assets — $31.4m $28.3m $25.1m $21.9m —
Operating Lease, Right-of-Use Asset $2.1m $7.3m $7.8m $7.6m $4.4m $1.6m
Right of use assets, net $2.1m $7.3m $7.8m $7.6m $4.4m $1.6m
Other assets — $804k $976k $882k $881k $930k
Additional Financial Items
Accounts Receivable, after Allowance for Credit Loss, Current $518k $20k $323k — — —
Restricted cash — — — $0 $1.7m $1.4m
Accrued expenses and other current liabilities $2.5m $7.9m $8.1m $9.2m $9.5m $6.2m
Deferred income — — — $0 $1.7m $1.4m
Contingent consideration — $2.4m $1.7m $1.8m $2.6m $2.9m
Other non-current liabilities — — $965k $1.3m $1.4m $1.5m
Ordinary shares, £0.000025 nominal value; 40,848,893 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 40,234,663) 0 1k 1k 1k 1k 1k
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 63,443) — — 94k 86k 86k 86k
Accumulated Depreciation — — ($1.3m) ($3.7m) ($9.4m) ($7.6m)
Capital Lease Obligations — — $8.8m $13.0m $12.0m $11.3m
Current Accrued Expenses — — $6.1m $6.8m $5.3m $6.2m
Current Capital Lease Obligation — — $433k $1.8m $1.9m $2.0m
Current Debt And Capital Lease Obligation — — $433k $1.8m $1.9m $2.0m
Current Deferred Liabilities — — $0 $0 $1.7m $1.4m
Duefrom Related Parties Current — $0 $5.5m — — —
Foreign Currency Translation Adjustments ($1.2m) ($8.5m) ($33.5m) ($23.3m) ($25.9m) ($15.7m)
Gross PPE — — $17.0m $23.1m $21.2m $12.8m
Invested Capital — — $242.9m $186.8m $130.0m $74.2m
Leases — — $3.9m $8.7m $9.3m $8.9m
Long Term Capital Lease Obligation — — $8.3m $11.2m $10.1m $9.3m
Machinery Furniture Equipment — — $1.0m $1.1m $1.3m $452k
Net PPE — — $15.7m $19.4m $11.8m $5.2m
Net Tangible Assets — — $202.4m $149.5m $108.1m $59.9m
Non Current Deferred Liabilities — — $3.7m $574k $438k $254k
Ordinary Shares Number — — $37.7m $38.6m $40.2m $40.8m
Other Equity Interest — — $94k $86k $86k $86k
Other Non Current Assets — — $976k $882k $881k $930k
Other Properties — — $12.1m $13.3m $10.6m $3.4m
Properties — — $0 $0 $0 $0
Share Issued — — $37.7m $38.6m $40.2m $40.8m
Tangible Book Value — — $202.4m $149.5m $108.1m $59.9m
Working Capital — — $200.8m $144.3m $110.1m $67.8m
Total stockholders’ equity attributable to Barinthus Biotherapeutics plc shareholders — $252.1m $242.9m $186.8m $130.0m $74.2m
Total stockholders’ equity ($36.9m) $252.6m $243.2m $187.0m $130.1m $74.3m
Total Capitalization — — $242.9m $186.8m $130.0m $74.2m
Total Debt — — $8.8m $13.0m $12.0m $11.3m
Total Non Current Assets — — $57.2m $57.6m $34.6m $20.4m
Total Tax Payable — — — $0 $2.4m $0
Assets $50.7m $280.7m $270.2m $214.5m $160.3m $98.2m
LIABILITIES AND EQUITY
Total liabilities and stockholders’ equity $50.7m $280.7m $270.2m $214.5m $160.3m $98.2m
Current liabilities:
Operating Lease, Liability, Current $192k $523k $433k $1.8m $1.9m $2.0m
Accounts Payable, Current $4.7m $2.4m $3.7m $1.6m $2.5m $350k
Operating Lease, Liability, Noncurrent $1.5m $6.5m $8.3m $11.2m $10.1m $9.3m
Current Deferred Revenue — — $0 $0 $1.7m $1.4m
Payables And Accrued Expenses — — $9.9m $8.4m $10.2m $6.6m
Liabilities, Current $7.6m $11.2m $12.2m $12.6m $15.7m $10.0m
Total current liabilities $7.6m $11.2m $12.2m $12.6m $15.7m $10.0m
Deferred Income Tax Liabilities, Net $1.6m $12.1m $12.7m $11.8m $438k $254k
Other Liabilities, Noncurrent — — $965k $1.3m $1.4m $1.5m
Deferred tax liability, net — $8.1m $3.7m $574k $438k $254k
Long Term Debt And Capital Lease Obligation — — $8.3m $11.2m $10.1m $9.3m
Non Current Deferred Taxes Liabilities — — $3.7m $574k $438k $254k
Pensionand Other Post Retirement Benefit Plans Current — — $1.9m $2.4m $1.8m $0
Deferred Tax Liabilities, Net — $8.1m $3.7m $574k — —
Liabilities $53.8m $28.2m $27.0m $27.5m $30.2m $23.9m
Stockholders’ equity:
Common Stock, Value, Issued $0 $1k $1k $1k $1k $1k
Additional Paid in Capital $21.7m $369.1m $379.5m $386.6m $393.5m $393.9m
Retained Earnings (Accumulated Deficit) ($57.7m) ($108.6m) ($103.2m) ($176.6m) ($237.7m) ($304.1m)
Capital Stock — — $1k $1k $1k $1k
Gains Losses Not Affecting Retained Earnings — — ($33.5m) ($23.3m) ($25.9m) ($15.7m)
Stockholders' Equity Attributable to Parent — — $242.9m $186.8m $130.0m $74.2m
Stockholders' Equity Attributable to Noncontrolling Interest $391k $437k $305k $211k $106k $84k
Minority Interest — — $305k $211k $106k $84k
Total Equity Gross Minority Interest — — $243.2m $187.0m $130.1m $74.3m
Total Non Current Liabilities Net Minority Interest — — $14.8m $14.9m $14.5m $13.9m
Liabilities and Equity $50.7m $280.7m $270.2m $214.5m $160.3m $98.2m

Amounts are shown in USD as reported in each fiscal year filing.